A rare case of clomiphene citrate induced moderate ovarian hyperstimulation syndrome
Keywords:Clomiphene citrate, Ovarian hyperstimulation syndrome, Ovulation induction
AbstractClomiphene citrate is an orally active non-steroidal triphenylethylene derivative which is commonly used for ovulation induction. It is considered a safe agent and is rarely associated with ovarian hyperstimulation syndrome. This report describes a case of moderate ovarian hyperstimulation syndrome after ovulation induction with clomiphene without associated pregnancy which was managed conservatively.
Mitchell SY, Fletcher HM, Williams E. Ovarian hyperstimulation syndrome associated with clomiphene citrate. West Indian Med J. 2001;50(3):227-9.
Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–96.
Nasseri S, Ledger WL. Clomiphene citrate in the twenty-first century. Hum Fertil (Camb). 2001;4(3):145-51.
Roge P, Emy R. Ovarian hyperstimulation syndrome in medically assisted reproduction. Rev Fr Gynecol Obstet. 1994;89(10):495-501.
Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005;33(10 Suppl):S301-6.
Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstet Gynaecol. 2005;15:132–8.
Alina OA, Luca A, Bors A. Principles of diagnosis and management in the ovarian hyperstimulation syndrome. Curr Health Sci J. 2013;39:187-92.
Klaus Fiedler, Diego Ezcurra. Predicting and preventing of Ovarian hyperstimulation syndrome(OHHS):the need for individualized not standardized treatment(management). Reprod Biol Endocrinol. 2012;10:32.